NCT02122172 2025-04-25
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Phase 2 Terminated
Clinical Trials
10 trialsNCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT01824823 2023-06-28
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT02115048 2019-12-26
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Translational Research in Oncology
Phase 2 Terminated
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT02271906 2019-04-30
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02131155 2019-03-01
LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim
Phase 3 Terminated
NCT01732640 2018-07-26
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT01345669 2017-12-07
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim
Phase 3 Terminated
NCT02695290 2017-09-18
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Boehringer Ingelheim
Phase 4 Terminated